| Literature DB >> 31827655 |
Catello Vollono1, Giacomo Della Marca1, Elisa Testani1, Anna Losurdo1, Daniela Virdis1, Diana Ferraro2, Valerio Brunetti1, Paolo M Rossini1,3, Domenica Le Pera3, Salvatore Mazza1, Massimiliano Valeriani4,5.
Abstract
Restless legs syndrome (RLS) is characterized by unpleasant sensations generally localized to legs, associated with an urge to move. A likely pathogenetic mechanism is a central dopaminergic dysfunction. The exact role of pain system is unclear. The purpose of the study was to investigate the nociceptive pathways in idiopathic RLS patients. We enrolled 11 patients (mean age 53.2 ± 19.7 years; 7 men) suffering from severe, primary RLS. We recorded scalp laser-evoked potentials (LEPs) to stimulation of different sites (hands and feet) and during two different time conditions (daytime and nighttime). Finally, we compared the results with a matched control group of healthy subjects. The Aδ responses obtained from patients did not differ from those recorded from control subjects. However, the N1 and the N2-P2 amplitudes' night/day ratios after foot stimulation were increased in patients, as compared to controls (N1: patients: 133.91 ± 50.42%; controls: 83.74 ± 34.45%; p = 0.016; Aδ-N2-P2: patients: 119.15 ± 15.56%; controls: 88.42 ± 23.41%; p = 0.003). These results suggest that RLS patients present circadian modifications in the pain system, which are not present in healthy controls. Both sensory-discriminative and affective-emotional components of pain experience show parallel changes. This study confirms the structural integrity of Aδ nociceptive system in idiopathic RLS, but it also suggests that RLS patients present circadian modifications in the pain system. These findings could potentially help clinicians and contribute to identify new therapeutic approaches.Entities:
Mesh:
Year: 2019 PMID: 31827655 PMCID: PMC6885267 DOI: 10.1155/2019/5408732
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Clinical and PSG data in RLS patients.
| Patient | Sex | Age | Duration | IRLSSG score | Sleep latency (min) | PLM index (events/h) | Comorbidity |
|---|---|---|---|---|---|---|---|
| #1 | M | 22 | 4 | 36 | 61 | 79 | HyperCKemia |
| #2 | F | 30 | 3 | 29 | 304 | 59 | Overweight |
| #3 | F | 68 | 12 | 30 | 20 | 14 | |
| #4 | F | 70 | 40 | 35 | 75 | 121 | |
| #5 | M | 64 | 30 | 27 | 13 | 25 | |
| #6 | M | 77 | 5 | 29 | 12 | 111 | |
| #7 | M | 40 | 1 | 23 | 18 | 5 | |
| #8 | M | 27 | 1 | 27 | 47 | 96 | |
| #9 | M | 58 | 40 | 32 | 21 | 156 | Glaucoma |
| #10 | F | 61 | 7 | 33 | 13 | 23 | |
| #11 | M | 68 | 2 | 29 | 103 | 247 | |
|
| 53.2 | 13.2 | 30.0 | 62.3 | 85.1 | ||
|
| 19.6 | 15.6 | 3.8 | 85.7 | 72.9 |
Polysomnographic data. Sleep latency: sleep-onset latency; PLM index: periodic limb movement index (number of events per hour).
Control subjects.
| CTR | Sex | Age | Sleep latency (min) | PLM index (events/h) |
|---|---|---|---|---|
| #1 | M | 60 | 17 | 5 |
| #2 | F | 71 | 18 | 18 |
| #3 | M | 49 | 11 | 13 |
| #4 | M | 38 | 21 | 3 |
| #5 | M | 74 | 9 | 0 |
| #6 | F | 58 | 20 | 4 |
| #7 | F | 64 | 25 | 4 |
| #8 | F | 29 | 7 | 6 |
| #9 | M | 71 | 19 | 4 |
| #10 | M | 21 | 11 | 9 |
| #11 | M | 74 | 14 | 16 |
|
| 55.4 | 15.6 | 7.5 | |
|
| 18.7 | 5.6 | 5.8 |
Polysomnographic data. Sleep latency: sleep-onset latency; PLM index: periodic limb movement index (number of events per hour).
VAS pain rating score.
| Foot | Night vs. day | Hand | Night vs. day | |||
|---|---|---|---|---|---|---|
| Night | Day | Night | Day | |||
| RLS | 55.64 ± 16.45 | 49.91 ± 12.77 |
| 55.91 ± 12.93 | 51.36 ± 10.92 |
|
|
| ||||||
| CTR | 34.73 ± 15.74 | 39.18 ± 19.49 |
| 31.64 ± 19.76 | 40.91 ± 20.31 |
|
|
| ||||||
| RLS vs. CTR |
|
|
|
| ||
Neurophysiological data.
| Foot | Night vs day | Hand | Night vs day | ||||
|---|---|---|---|---|---|---|---|
| Night | Day | Night | Day | ||||
| N1 latency (ms) | RLS | 149.5 ± 32.8 | 165.2 ± 34.2 |
| 151.7 ± 36.6 | 155.7 ± 31.8 |
|
| CTR | 172.4 ± 30.0 | 174.1 ± 30.0 |
| 143.6 ± 24 | 152.3 ± 33.2 |
| |
|
| |||||||
| RLS vs. CTR |
|
|
|
| |||
|
| |||||||
| N1 amplitude ( | RLS | 3.1 ± 1.1 | 2.7 ± 2.4 |
| 3.8 ± 2.6 | 3.6 ± 2 |
|
| CTR | 3.7 ± 1.5 | 4.8 ± 2.0 |
| 4.5 ± 2.7 | 5.2 ± 1.5 |
| |
|
| |||||||
| RLS vs. CTR |
|
|
|
| |||
|
| |||||||
| N2 latency (ms) | RLS | 226.7 ± 46.8 | 238.9 ± 54.4 |
| 218.8 ± 54.4 | 234.2 ± 56.4 |
|
| CTR | 236.8 ± 26.0 | 223.2 ± 33.1 |
| 201.8 ± 31.2 | 197.5 ± 36.5 |
| |
|
| |||||||
| RLS vs. CTR |
|
|
|
| |||
|
| |||||||
| P2 latency (ms) | RLS | 396.6 ± 83.4 | 372.7 ± 60.9 |
| 351.8 ± 60.4 | 365.8 ± 72.6 |
|
| CTR | 364.8 ± 29.9 | 353.2 ± 31.0 |
| 318.8 ± 37.9 | 322.4 ± 41.7 |
| |
|
| |||||||
| RLS vs. CTR |
|
|
|
| |||
|
| |||||||
| N2-P2 amplitude ( | RLS | 13.6 ± 5.2 | 11.5 ± 4.0 |
| 10.7 ± 5.1 | 11.1 ± 4.7 |
|
| CRL | 12.4 ± 7.1 | 15 ± 9.0 |
| 14.1 ± 8.6 | 16.9 ± 11.1 |
| |
|
| |||||||
| RLS vs. CTR |
|
|
|
| |||
Figure 1Laser-evoked potentials (LEP) obtained after foot and hand stimulation in an RLS patient (a) and a control subject (b). The figure shows, in RLS patient, that both Aδ-N1 and Aδ-N2-P2 amplitudes after foot stimulation are increased during night when compared to daytime recordings. Conversely, LEP amplitude after hand stimulation results in unmodified night and day stimulation. In control subject, LEP amplitudes are substantially unchanged in two sessions after foot and hand stimulation.
Neurophysiological data: night/day ratio.
| Foot | Hand | ||||
|---|---|---|---|---|---|
| N1 latency | RLS | 94.2 ± 10.6 |
| 98.8 ± 21.7 |
|
| CTR | 99.8 ± 12.5 | 95.7 ± 10.3 | |||
|
| |||||
| N1 amplitude | RLS | 133.9 ± 50.4 |
| 135.2 ± 124.5 |
|
| CTR | 83.7 ± 34.5 | 87.5 ± 41.4 | |||
|
| |||||
| N2 latency | RLS | 100.3 ± 13.7 |
| 95.2 ± 16.3 |
|
| CTR | 106.0 ± 12.0 | 103.5 ± 14.9 | |||
|
| |||||
| P2 latency | RLS | 106.2 ± 12.6 |
| 96.8 ± 6.6 |
|
| CTR | 103.6 ± 8.2 | 99.4 ± 9.1 | |||
|
| |||||
| N2-P2 amplitude | RLS | 119.2 ± 15.6 |
| 100.2 ± 35.5 |
|
| CTR | 88.4 ± 23.4 | 86.2 ± 22.6 | |||